placeNew Zealand
Contact Us
Minimally Invasive Therapies / Products / Cerebral/Somatic Oximetry / INVOS™ Perspective / Patient Outcomes / INVOS™ System

Overview

Only the INVOS system has been proven to be clinically effective in providing clinicians with physiologic insights into a patient’s status to make care-management decisions that contribute to improving patient outcomes.

  • It is the ONLY cerebral oximeter on the market that is validated via a published hypoxia study under different levels of PaCO2.1
  • Using an optimised emitter spacing configuration, the INVOS system demonstrates sensitivity to subtle changes in saturation and cerebral blood flow.2

Another manufacturer’s disclaimer—accurate when patients are “normal”

A device made by a competitor is designed to determine regional haemoglobin oxygen saturation of blood underneath the sensor, according to the manufacturer.3 Its performance and accuracy of the device can be degraded or impacted if the patient’s CO2 levels are non-normocapnic (non-normal) or if there are other conditions that affect blood volume.2

Do your patients always have “normal” CO2 levels?

  • 1. Kim M, Ward D, Cartwright C, et al. Estimation of jugular venous O2 saturation from cerebral oximetry or arterial O2 saturation during isocapnic hypoxia. J Clin Monit Comput. 2000;16(3):191-99.
  • 2. Hongo K, Kobayashi S, Okudera H, Hokama M, Nakagawa F. Noninvasive cerebral optical spectroscopy. Depth-resolved measurements of cerebral haemodynamics using indocyanine green. Neurol Res. 1995;17(2):89-93.
  • 3. NONIN Operator’s Manual Model 7600, Page 3, Cautions.
About Medtronic
Minimally Invasive Therapies
Contact Us
Country Office

Level 3 - Building 5

Central Corporate Centre

666 Great South Road

Penrose, Auckland

New Zealand

©2025 Medtronic